Galectin-3 is an independent predictor of survival in systemic sclerosis

Réka Faludi, Gabriella Nagy, Margit Tőkés-Füzesi, Krisztina Kovács, L. Czirják, András Komócsi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background Galectin-3 is a beta-galactoside-binding lectin that may be related to tissue sclerosis or aberrant activation of angiogenesis in systemic sclerosis (SSc). The aim of our study was to determine the associations between galectin-3 levels and patient characteristics, as well as to investigate the long term prognostic value of galectin-3 in a large cohort of SSc patients. Methods 152 patients with SSc (55 ± 11 years, 138 female) were included in our follow-up study. Blood samples and clinical data were collected at baseline. Primary and secondary outcomes were all-cause and cardiovascular mortality, respectively. Resultss Galectin-3 levels showed positive correlation with the grade of left ventricular diastolic function (r = 0.193; p = 0.026), erythrocyte sedimentation rate (r = 0.172; p = 0.036) and serum level of C-reactive protein (r = 0.200; p = 0.015) while negative correlation with diffusing capacity for carbon monoxide (r = − 0.228; p = 0.006), in age, gender and BSA adjusted analyses. During the follow-up of 7.2 ± 2.3 years, 35 SSc patients (23%) died. In multivariate Cox regression analyses adjusted for age, gender, BSA, creatinine and NT-proBNP levels, galectin-3 was an independent predictor both of the all-cause mortality (HR: 2.780, 95% CI: 1.320–5.858, p = 0.007) and cardiovascular mortality (HR: 3.346, 95% CI: 1.118–10.012, p = 0.031). Using receiver-operating characteristic analysis, galectin-3 > 10.25 ng/ml was found to be the best predictor of the all-cause mortality. Conclusions Our results suggest that galectin-3 is an independent predictor of all-cause and cardiovascular mortality in SSc. Validation studies are required to establish whether galectin-3 may be proposed as simple biomarker for identifying patients with high mortality risk in SSc.

Original languageEnglish
Pages (from-to)118-124
Number of pages7
JournalInternational Journal of Cardiology
Volume233
DOIs
Publication statusPublished - Apr 15 2017

Fingerprint

Galectin 3
Systemic Scleroderma
Survival
Mortality
Galectins
Validation Studies
Blood Sedimentation
Sclerosis
Carbon Monoxide
Left Ventricular Function
ROC Curve
C-Reactive Protein
Creatinine
Biomarkers
Regression Analysis

Keywords

  • All-cause mortality
  • Cardiovascular mortality
  • Galectin-3
  • NT-proBNP
  • Systemic sclerosis

ASJC Scopus subject areas

  • Medicine(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Galectin-3 is an independent predictor of survival in systemic sclerosis. / Faludi, Réka; Nagy, Gabriella; Tőkés-Füzesi, Margit; Kovács, Krisztina; Czirják, L.; Komócsi, András.

In: International Journal of Cardiology, Vol. 233, 15.04.2017, p. 118-124.

Research output: Contribution to journalArticle

Faludi, Réka ; Nagy, Gabriella ; Tőkés-Füzesi, Margit ; Kovács, Krisztina ; Czirják, L. ; Komócsi, András. / Galectin-3 is an independent predictor of survival in systemic sclerosis. In: International Journal of Cardiology. 2017 ; Vol. 233. pp. 118-124.
@article{855ba1564431475fbbd647545fc546e9,
title = "Galectin-3 is an independent predictor of survival in systemic sclerosis",
abstract = "Background Galectin-3 is a beta-galactoside-binding lectin that may be related to tissue sclerosis or aberrant activation of angiogenesis in systemic sclerosis (SSc). The aim of our study was to determine the associations between galectin-3 levels and patient characteristics, as well as to investigate the long term prognostic value of galectin-3 in a large cohort of SSc patients. Methods 152 patients with SSc (55 ± 11 years, 138 female) were included in our follow-up study. Blood samples and clinical data were collected at baseline. Primary and secondary outcomes were all-cause and cardiovascular mortality, respectively. Resultss Galectin-3 levels showed positive correlation with the grade of left ventricular diastolic function (r = 0.193; p = 0.026), erythrocyte sedimentation rate (r = 0.172; p = 0.036) and serum level of C-reactive protein (r = 0.200; p = 0.015) while negative correlation with diffusing capacity for carbon monoxide (r = − 0.228; p = 0.006), in age, gender and BSA adjusted analyses. During the follow-up of 7.2 ± 2.3 years, 35 SSc patients (23{\%}) died. In multivariate Cox regression analyses adjusted for age, gender, BSA, creatinine and NT-proBNP levels, galectin-3 was an independent predictor both of the all-cause mortality (HR: 2.780, 95{\%} CI: 1.320–5.858, p = 0.007) and cardiovascular mortality (HR: 3.346, 95{\%} CI: 1.118–10.012, p = 0.031). Using receiver-operating characteristic analysis, galectin-3 > 10.25 ng/ml was found to be the best predictor of the all-cause mortality. Conclusions Our results suggest that galectin-3 is an independent predictor of all-cause and cardiovascular mortality in SSc. Validation studies are required to establish whether galectin-3 may be proposed as simple biomarker for identifying patients with high mortality risk in SSc.",
keywords = "All-cause mortality, Cardiovascular mortality, Galectin-3, NT-proBNP, Systemic sclerosis",
author = "R{\'e}ka Faludi and Gabriella Nagy and Margit Tők{\'e}s-F{\"u}zesi and Krisztina Kov{\'a}cs and L. Czirj{\'a}k and Andr{\'a}s Kom{\'o}csi",
year = "2017",
month = "4",
day = "15",
doi = "10.1016/j.ijcard.2016.12.140",
language = "English",
volume = "233",
pages = "118--124",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Galectin-3 is an independent predictor of survival in systemic sclerosis

AU - Faludi, Réka

AU - Nagy, Gabriella

AU - Tőkés-Füzesi, Margit

AU - Kovács, Krisztina

AU - Czirják, L.

AU - Komócsi, András

PY - 2017/4/15

Y1 - 2017/4/15

N2 - Background Galectin-3 is a beta-galactoside-binding lectin that may be related to tissue sclerosis or aberrant activation of angiogenesis in systemic sclerosis (SSc). The aim of our study was to determine the associations between galectin-3 levels and patient characteristics, as well as to investigate the long term prognostic value of galectin-3 in a large cohort of SSc patients. Methods 152 patients with SSc (55 ± 11 years, 138 female) were included in our follow-up study. Blood samples and clinical data were collected at baseline. Primary and secondary outcomes were all-cause and cardiovascular mortality, respectively. Resultss Galectin-3 levels showed positive correlation with the grade of left ventricular diastolic function (r = 0.193; p = 0.026), erythrocyte sedimentation rate (r = 0.172; p = 0.036) and serum level of C-reactive protein (r = 0.200; p = 0.015) while negative correlation with diffusing capacity for carbon monoxide (r = − 0.228; p = 0.006), in age, gender and BSA adjusted analyses. During the follow-up of 7.2 ± 2.3 years, 35 SSc patients (23%) died. In multivariate Cox regression analyses adjusted for age, gender, BSA, creatinine and NT-proBNP levels, galectin-3 was an independent predictor both of the all-cause mortality (HR: 2.780, 95% CI: 1.320–5.858, p = 0.007) and cardiovascular mortality (HR: 3.346, 95% CI: 1.118–10.012, p = 0.031). Using receiver-operating characteristic analysis, galectin-3 > 10.25 ng/ml was found to be the best predictor of the all-cause mortality. Conclusions Our results suggest that galectin-3 is an independent predictor of all-cause and cardiovascular mortality in SSc. Validation studies are required to establish whether galectin-3 may be proposed as simple biomarker for identifying patients with high mortality risk in SSc.

AB - Background Galectin-3 is a beta-galactoside-binding lectin that may be related to tissue sclerosis or aberrant activation of angiogenesis in systemic sclerosis (SSc). The aim of our study was to determine the associations between galectin-3 levels and patient characteristics, as well as to investigate the long term prognostic value of galectin-3 in a large cohort of SSc patients. Methods 152 patients with SSc (55 ± 11 years, 138 female) were included in our follow-up study. Blood samples and clinical data were collected at baseline. Primary and secondary outcomes were all-cause and cardiovascular mortality, respectively. Resultss Galectin-3 levels showed positive correlation with the grade of left ventricular diastolic function (r = 0.193; p = 0.026), erythrocyte sedimentation rate (r = 0.172; p = 0.036) and serum level of C-reactive protein (r = 0.200; p = 0.015) while negative correlation with diffusing capacity for carbon monoxide (r = − 0.228; p = 0.006), in age, gender and BSA adjusted analyses. During the follow-up of 7.2 ± 2.3 years, 35 SSc patients (23%) died. In multivariate Cox regression analyses adjusted for age, gender, BSA, creatinine and NT-proBNP levels, galectin-3 was an independent predictor both of the all-cause mortality (HR: 2.780, 95% CI: 1.320–5.858, p = 0.007) and cardiovascular mortality (HR: 3.346, 95% CI: 1.118–10.012, p = 0.031). Using receiver-operating characteristic analysis, galectin-3 > 10.25 ng/ml was found to be the best predictor of the all-cause mortality. Conclusions Our results suggest that galectin-3 is an independent predictor of all-cause and cardiovascular mortality in SSc. Validation studies are required to establish whether galectin-3 may be proposed as simple biomarker for identifying patients with high mortality risk in SSc.

KW - All-cause mortality

KW - Cardiovascular mortality

KW - Galectin-3

KW - NT-proBNP

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85009437483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009437483&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2016.12.140

DO - 10.1016/j.ijcard.2016.12.140

M3 - Article

C2 - 28043664

AN - SCOPUS:85009437483

VL - 233

SP - 118

EP - 124

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -